Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525688 | 1.00 | DDB1 (0.67) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL21759957 | 1.00 | DDB1 (0.67) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL30317044 | 0.92 | DDB1 (0.63) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL23986322 | 0.92 | DDB1 (0.63) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL22511565 | 0.92 | DDB1 (0.66) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL21069260 | 0.92 | DDB1 (0.66) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL21996955 | 0.91 | DDB1 (0.65) | DDB1CRBNIKZF3 | |
| SCHEMBL23946051 | 0.91 | DDB1 (0.65) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL21997261 | 0.91 | DDB1 (0.65) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL27377387 | 0.91 | DDB1 (0.67) | DDB1CRBNIKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | DDB1 3837/4885CRBN 183/4885IKZF3 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.